Maricann Group Inc. Receives Encapsulated Cannabis Oil Licence from Health Canada
TORONTO, Ontario, November 20, 2017 – Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company") through its wholly owned subsidiary, Maricann Inc. has commenced production of encapsulated cannabis oil, following receipt of its production license from Health Canada on November 17, 2017. Maricann expects patients to be able to order oil capsules starting in Q1 2018, subject to Health Canada's issuance of the required license to sell.
Maricann Capsules are a critical innovation in medicinal cannabis therapy as they deliver medicine in a dosage form widely utilized in the pharmaceutical industry, provide precise dosing in each capsule, enhance patient compliance and will be formulated to support therapeutic efficacy. All natural cannabis extract will be delivered in a vegan capsule format, initially in four products: 15mg and 25mg cannabidiol (CBD) capsules and 5mg and 10mg THC capsules, allowing physicians and patients to more easily control dosing and choose the cannabinoid therapy they prefer. In parallel, Maricann will commence production of its exclusive and patented VesiSorb™ technology in capsule format. VesiSorb™ is approved in the delivery of other lipophilic (fat-soluble pharmaceutical and nutraceutical formulations) drugs by Health Canada, the US Food and Drug Administration and European Medicines Agency. Application of VesiSorb is not limited to capsules, but spans entire product categories of ingestibles, including capsules, edibles and functional beverages. See the VesiSorb difference in the following link: VesiSorb
"Physicians and patients understand metered dose capsules, they're a part of daily life. Vaporizing and smoking aren't something people new to cannabis are familiar or comfortable with, so we believe that providing them with a treatment option in a delivery format they understand is compelling," said Ben Ward, CEO of Maricann. "Medicinal cannabinoids have anectdotally demonstrated therapeutic benefit for a wide range of symptoms; however, cannabinoids are nearly insoluble in water. Their poor solubility and low dissolution rate in the aqueous gastrointestinal fluids and significant first-pass liver metabolism result in low and unpredictable oral cannabinoid bioavailability. Consequentially, cannabinoids will require high doses to reach therapeutic plasma concentrations, especially when ingested. At Maricann, we are focused on formulations that actually potentiate the components of the cannabis plant."
Maricann offers true differentiation with our full acquisition of the global rights for Vesisorb technology for phytocannabinoids (see press release dated August 22, 2017). Vesisorb is a proprietary patented lipid based nano-colloidal drug delivery technology that delivers standardized profiles of whole plant extracts, in convenient, microliter dosages with increased bioavailability, bioactivity and therapeutic potential. This is a major advancement in lipophilic drug delivery technology.
About Maricann Group Inc.
Maricann, which has federal licenses in Canada to cultivate, extract, formulate and distribute cannabis, is rapidly expanding its Canadian production, based in Norfolk County, Ontario, adding 22,245 kg of annual production of dry flower to come online in Q2 2018, with additional production planned. Maricann is focused on expanding capacity in a truly differentiated product offering, in support of its previously announced joint pharmacy initiative and future global export opportunities.
For more information about Maricann, please visit our website at www.maricann.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward Looking Information
Certain statements in this document contain forward-looking statements which can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "desires", "will", "should", "projects", "estimates", "contemplates", "anticipates", "intends", or any negative such as "does not believe" or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. The forward looking statements in this release include statements regarding the planned increase in annual production and the availability of cannabis oil capsules in Q1 2018. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management's control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; failure to obtain required financing; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. The reader is cautioned not to place undue reliance on forward-looking information.
Maricann Group Inc.
Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
European Headquarters (Germany)
Thierschstrasse 3, 80538 Munchen, Deutschland